Schilling M K, Büchler M W
Klinik für Viszerale und Transplantationschirurgie, Universität Bern, Inselspital.
Ther Umsch. 1998 Jul;55(7):435-8.
Esophageal cancer is one of the most malignant tumors in man. A better understanding of the biology of esophageal cancer as well as surgical technical advances have significantly improved the treatment of esophageal cancer patients. A careful risk analysis is crucial for a reduced postoperative mortality and anastomotic failure rate and neoadjuvant therapy facilitates down staging of tumours, thus aiding in high resectability rates with significantly improved long term survival in patients with esophageal cancer.
食管癌是人类最恶性的肿瘤之一。对食管癌生物学的更好理解以及手术技术的进步显著改善了食管癌患者的治疗。仔细的风险分析对于降低术后死亡率和吻合口失败率至关重要,新辅助治疗有助于肿瘤降期,从而提高可切除率,并显著提高食管癌患者的长期生存率。